2022/11/29 更新

写真a

アネンコフ アレクセイ
ANNENKOV ALEXEY
ANNENKOV ALEXEY
所属
教育研究院 医歯学系 特任助教
医歯学総合研究科 特任助教
職名
特任助教
外部リンク

学位

  • 博士(医学) ( 2012年9月   新潟大学 )

経歴

  • 新潟大学   医歯学総合研究科   特任助教

    2022年4月 - 現在

  • 新潟大学   教育研究院 医歯学系   特任助教

    2022年4月 - 現在

  • 新潟大学   研究推進機構 超域学術院   助教

    2019年4月 - 2022年3月

  • 新潟大学   研究推進機構 超域学術院   特任助教

    2018年1月 - 2019年3月

  • 新潟大学   医歯学総合研究科   特任助教

    2015年2月 - 2017年12月

 

論文

  • [Two Cases of Surgical Treatment for Disseminated Gastric Carcinoma].

    Makoto Aoki, Hiroyuki Fukunari, Yosuke Kawai, Akemi Watanabe, Yuya Umebayashi, Toshifumi Saito, Kenji Shitara, Tetsuji Hayashi, Annenkov Alexey, Yoichi Ajioka

    Gan to kagaku ryoho. Cancer & chemotherapy   45 ( 13 )   2378 - 2380   2018年12月

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)  

    Case 1: A 75-year-old man underwent distal gastrectomy with Billroth Ⅰ reconstruction and resection of the involved transverse mesocolon. Microscopic examination revealed adenocarcinoma(tub2, tub1), pT4b(SI)N3M0, pStageⅢc. Adjuvant chemotherapy with S-1 was performed for 6 months after the operation. One year later, CT revealed a localized dissemination in the transverse mesocolon; therefore, we performed transverse colectomy. Adjuvant chemotherapy with PTX was performed, and the patient remains free from recurrence 7 years after the initialoperation. Case 2: A 65-year-old man was diagnosed with gastric scirrhous carcinoma by esophagogastroduodenoscopy. CT and colonoscopy showed a tumorous lesion in the pelvis(Schnitzler's metastasis). Neo-adjuvant chemotherapy with S-1 plus CDDP was performed. After 6 courses, CT and endoscopy showed shrinkage of the tumors, and no other distant metastasis was detected by PET-CT. We performed totalgastrectomy(D2), splenectomy, and low anterior resection of the rectum simultaneously. Microscopic examination revealed adenocarcinoma(tub2, por2, sig), pT4a(SE)N0, and the histological response was Grade 1a. S-1 was administered, and the patient has had no recurrence in the 1 year 6 months after the operation. Dissemination of gastric cancer tends to be difficult to treat and has a poor prognosis. However, in some cases, the proper combination of chemotherapy and surgery might be beneficial for long survival.

    PubMed

    researchmap

  • Intestinal metaplasia in Barrett's oesophagus may be an epiphenomenon rather than a preneoplastic condition, and CDX2-positive cardiac-type epithelium is associated with minute Barrett's tumour. 国際誌

    Gen Watanabe, Yoichi Ajioka, Manabu Takeuchi, Alexey Annenkov, Takashi Kato, Kaori Watanabe, Yusuke Tani, Kikuo Ikegami, Yoko Yokota, Mutsumi Fukuda

    Histopathology   66 ( 2 )   201 - 14   2015年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    AIMS: Although intestinal-type epithelium in Barrett's oesophagus has been traditionally recognized as having a distinct malignant potential, whether this also holds true for cardiac-type epithelium remains controversial. The aim of this study was to identify a type of epithelium that is highly associated with Barrett's tumour. METHODS AND RESULTS: We analysed tumours and the corresponding background mucosa with special regard to tumour size in 40 cases of superficial Barrett's tumour by using immunohistochemical staining for CDX2, CD10, MUC2, MUC5AC, and MUC6. Intestinal metaplasia in tumour-adjacent mucosa was not associated with tumour size, but was significantly correlated with the extent of Barrett's oesophagus (P < 0.001). The majority (69.2%, 9/13) of small tumours (≤10 mm) had no intestinal metaplasia in adjacent non-neoplastic mucosae. Minute (≤5 mm) tumours were significantly associated with a gastric immunophenotype (P < 0.001). Purely gastric-immunophenotype tumour cells expressed CDX2, and cardiac-type epithelium adjacent to small tumours also showed low-level CDX2 expression. CONCLUSIONS: Our data suggest that intestinal metaplasia in Barrett's oesophagus is an epiphenomenon rather than a preneoplastic condition, and that CDX2-positive cardiac-type epithelium is highly associated with minute Barrett's tumour. Further prospective studies are needed to evaluate the risk of malignancy of cardiac-type epithelium with regard to sub-morphological intestinalization.

    DOI: 10.1111/his.12486

    PubMed

    researchmap

  • Alpha-methylacyl-coenzyme A racemase expression in neuroendocrine neoplasms of the stomach. 国際誌

    Alexey Annenkov, Ken Nishikura, Koji Domori, Yoichi Ajioka

    Virchows Archiv : an international journal of pathology   461 ( 2 )   169 - 75   2012年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    The enzyme alpha-methylacyl-coenzyme A racemase plays an important role in the beta-oxidation of branched-chain fatty acid and its derivatives. It has been used to detect prostatic adenocarcinoma and high-grade intraepithelial neoplasia, and recently also as a marker for other neoplasms, including those of the genitourinary system, breast, upper and lower gastrointestinal tract and their precursor lesions. We assessed expression of alpha-methylacyl-coenzyme A racemase by immunohistochemistry in neuroendocrine tumours of the stomach to determine differences in the incidence and pattern of expression among different types of gastric neuroendocrine tumours. While none of the grade 1 neuroendocrine tumours were immunoreactive, 67 % of grade 2 neuroendocrine tumours and 90 % of neuroendocrine carcinomas were positive for alpha-methylacyl-coenzyme A racemase. Furthermore, an adenocarcinoma component was found in 72.5 % (37 of 51) of neuroendocrine carcinomas, whereas none of the grade 1 and 2 neuroendocrine tumours contained an adenocarcinoma component. In 83 % of neuroendocrine carcinomas, the adenocarcinoma component was positive for alpha-methylacyl-coenzyme A racemase, and both adenocarcinoma and neuroendocrine carcinoma components stained positively in 78 % of these cases. Our results indicate that alpha-methylacyl-coenzyme A racemase is a useful marker for distinguishing between grade 1 (negative) and grade 2 neuroendocrine tumours, and neuroendocrine carcinoma of the stomach (frequently positive). Different patterns of alpha-methylacyl-coenzyme A racemase expression between gastric neuroendocrine tumours and neuroendocrine carcinoma suggest that these might develop via different tumourigenic pathways.

    DOI: 10.1007/s00428-012-1272-5

    PubMed

    researchmap